Cardiovascular disease is one of the most significant public health issues in the world. Our commitment to cardiovascular disease remains steadfast, and supporting cross-sector collaborative programs and patient-advocacy initiatives is part of this commitment. A key focus of this work is moving from a reactive healthcare model toward a proactive and innovative public health approach aimed to predict and prevent the impact of serious diseases from occurring. Together, we are employing and testing not just one approach but a range of innovative initiatives to help improve patient outcomes and address population health.
The AHA’s Lower Your LDL Cholesterol Now™ initiative is sponsored nationally by Amgen and aims to educate on the importance of addressing LDL.
CardioHealth Alliance’s new project sponsored by Amgen aims to assess and improve quality of care among patients hospitalized for ASCVD.
The LDL-C Action Summit is an initiative among members of the CVD community to collaboratively address the state of cardiovascular care in the U.S.
LDL-C is a modifiable risk factor for CVD, but it's not about numbers — it's about intervening early, creating a treatment plan, and taking action.
Understand why it’s important to prioritize Black/African American representation in ASCVD clinical research.
ASCVD: atherosclerotic cardiovascular disease, LDL: low-density lipoprotein, LDL-C: low-density lipoprotein-cholesterol